Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) EBT Margin: 2012-2025

Historic EBT Margin for Sunshine Biopharma (SBFM) over the last 12 years, with Sep 2025 value amounting to -10.84%.

  • Sunshine Biopharma's EBT Margin rose 80.00% to -10.84% in Q3 2025 from the same period last year, while for Sep 2025 it was -17.44%, marking a year-over-year decrease of 496.00%. This contributed to the annual value of -15.40% for FY2024, which is 167.00% up from last year.
  • As of Q3 2025, Sunshine Biopharma's EBT Margin stood at -10.84%, which was up 48.46% from -21.04% recorded in Q2 2025.
  • Sunshine Biopharma's 5-year EBT Margin high stood at 783.75% for Q4 2021, and its period low was -15,440.43% during Q1 2021.
  • Its 3-year average for EBT Margin is -16.27%, with a median of -13.71% in 2025.
  • In the last 5 years, Sunshine Biopharma's EBT Margin slumped by 1,459,140bps in 2021 and then skyrocketed by 1,443,245bps in 2022.
  • Over the past 5 years, Sunshine Biopharma's EBT Margin (Quarterly) stood at 783.75% in 2021, then slumped by 137,462bps to -590.86% in 2022, then skyrocketed by 57,745bps to -13.41% in 2023, then tumbled by 1,043bps to -23.83% in 2024, then spiked by 80bps to -10.84% in 2025.
  • Its last three reported values are -10.84% in Q3 2025, -21.04% for Q2 2025, and -13.71% during Q1 2025.